文献速递瓣膜病与结构性心脏病

无症状重度主动脉瓣狭窄患者的心脏生物标志物:EARLY TAVR 试验分析

Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.
PubMed 文献 · Circulation · 2025-03-31

EARLY TAVR 试验纳入 901 例无症状重度主动脉瓣狭窄患者,其中 798 例检测了 NT-proBNP 和 hs-cTnT。生物标志物水平升高与多个终点事件率升高相关,但早期 TAVR 的相对获益在各生物标志物水平间总体一致,且倾向于在生物标志物水平最低的患者中更明显。

要点

  • NT-proBNP 和 hs-cTnT 升高与无症状重度 AS 患者事件率升高相关。
  • 早期 TAVR 的相对获益不因基线生物标志物水平而显著改变。
  • 单次生物标志物测量对指导无症状 AS 患者 TAVR 时机价值有限。

核心结论

  • 在无症状重度高跨瓣压差主动脉瓣狭窄患者中,较高的 NT-proBNP 和 hs-cTnT 水平与更高的多个终点事件率相关。
  • 早期 TAVR 策略的相对获益在各基线生物标志物水平间总体一致,且与假设相反,倾向于在生物标志物水平最低的患者中更明显。
  • 这些发现提示单次测量这些生物标志物对指导无症状患者 TAVR 时机的价值有限。

研究设计与样本

  • EARLY TAVR 试验(NCT03042104)的二次分析,共 901 例患者随机分组,其中 798 例(89%)有生物标本检测。
  • 由核心实验室测量 NT-proBNP 和 hs-cTnT 水平。
  • 采用 Kaplan-Meier 曲线和 Cox 比例风险模型分析生物标志物与终点事件的关系,并进行交互检验评估早期 TAVR 疗效是否因生物标志物水平而异。

主要发现

  • 中位 NT-proBNP 水平为 287(145, 601),中位 hs-cTnT 水平为 14.6(10.5, 21.0)。
  • 较高的 NT-proBNP 和 hs-cTnT 水平广泛与多个终点事件率升高相关。
  • 基线生物标志物与治疗组之间对任何复合或个体终点总体上无显著交互作用,但趋势广泛显示早期 TAVR 在较低生物标志物水平时相对获益更大。
  • hs-cTnT 水平与治疗组对死亡或心衰住院(P 交互=0.04)及单纯心衰住院(P 交互=0.03)存在显著交互作用,早期 TAVR 的相对获益在基线 hs-cTnT 正常而非升高的患者中更大。
  • 对于某些终点,较高的基线 NT-proBNP 水平与早期 TAVR 的数值上更大的绝对风险降低相关。

临床怎么用

  • 不应仅依据单次 NT-proBNP 或 hs-cTnT 测量来决定无症状重度 AS 患者 TAVR 的时机。
  • 早期 TAVR 的相对获益在各生物标志物水平间总体一致,生物标志物水平低并非推迟干预的理由。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The EARLY TAVR trial (Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis) demonstrated that early transcatheter aortic valve replacement (TAVR) intervention was superior to clinical surveillance with delayed TAVR in patients with asymptomatic severe aortic stenosis. Cardiac biomarkers are associated with maladaptive remodeling, symptom onset, and worse outcomes after TAVR. Whether elevated biomarkers identify asymptomatic patients more likely to benefit from early intervention is unknown. METHODS: A core laboratory measured NT-proBNP (N-terminal pro-B-type natriuretic peptide) and high-sensitivity cardiac troponin T (hs-cTnT) levels. Associations between biomarker levels and risk of the trial primary end point (death, stroke, or unplanned cardiovascular hospitalization) and other secondary end points were examined with Kaplan-Meier curves and Cox proportional hazard models. Interaction tests were performed to assess whether the treatment effect of early TAVR, compared with clinical surveillance, differed according to biomarker levels. RESULTS: Among 901 patients randomized in EARLY TAVR, 798 (89%) had biospecimens measured (median NT-proBNP level, 287 [145, 601]; median hs-cTnT level, 14.6 [10.5, 21.0]). Higher levels of NT-proBNP and hs-cTnT were broadly associated with higher event rates for multiple end points. In general, there was no significant interaction between baseline biomarkers and treatment group with respect to any composite or individual end point examined, although trends broadly demonstrated a greater relative benefit of early TAVR at lower biomarker levels. There was a significant interaction between hs-cTnT level and treatment group with respect to death or heart failure hospitalization (P interaction=0.04) and heart failure hospitalization alone (P interaction=0.03) such that the relative benefit of early TAVR was greater for patients with normal, rather than elevated, levels of hs-cTnT at baseline. For some end points, higher baseline NT-proBNP level was associated with numerically greater absolute risk reduction with early TAVR than were lower NT-proBNP levels. CONCLUSIONS: In patients with asymptomatic severe high-gradient aortic stenosis, higher NT-proBNP and hs-cTnT levels were broadly associated with higher event rates, as expected. However, the relative benefit of an early TAVR strategy was consistent regardless of baseline biomarker levels and, contrary to our hypothesis, tended to be more pronounced in patients with the lowest biomarker levels. These findings suggest limited value for single measurements of these biomarkers to guide the timing of TAVR in asymptomatic patients. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03042104.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Lindman BR, Pibarot P, Schwartz A, et al. Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial. Circulation. 2025. PMID: 40163596. doi:10.1161/CIRCULATIONAHA.125.074425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。